Evogene (EVGN) Research & Development (2012 - 2026)
Evogene (EVGN) posted Research & Development of $1.8 million for Q1 2026, up 0.66% sequentially from $1.8 million in Q4 2025, and down 25.58% YoY from $2.5 million in Q1 2025.
Evogene (EVGN) Research & Development (2012 - 2026) Analysis & Trends
Evogene has reported Research & Development for 15 years, with the latest figure at $1.8 million in Q1 2026.
- Quarterly Research & Development fell 25.58% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.4 million (down 35.22% YoY) and the FY2025 annual result came in at $8.0 million, down 36.1% from the prior year.
- Research & Development improved to $1.8 million in Q1 2026 per EVGN's latest filing, from $1.8 million in the prior quarter.
- Over five years, Research & Development peaked at $5.6 million in Q1 2022 and troughed at $1.4 million in Q3 2025.
- A 5-year average of $3.8 million and a median of $4.8 million in 2022 frame the typical range for Research & Development.
- The sharpest annual moves came in 2022 and 2025: Research & Development jumped 30.93% in 2022, then slumped 58.4% in 2025.
- Over 5 years, Research & Development stood at $4.8 million in 2022, then gained by 16.66% to $5.5 million in 2023, then sank by 51.18% to $2.7 million in 2024, then sank by 32.51% to $1.8 million in 2025, then climbed by 0.66% to $1.8 million in 2026.
- According to Business Quant data, Research & Development over the past three periods registered $1.8 million, $1.8 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | 1.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.84 Mn |
| Dec 31, 2025 | 1.83 Mn |
| Sep 30, 2025 | 1.38 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | 2.47 Mn |
| Dec 31, 2024 | 2.71 Mn |
| Sep 30, 2024 | 3.31 Mn |
| Jun 30, 2024 | 2.88 Mn |
| Mar 31, 2024 | 4.80 Mn |
| Dec 31, 2023 | 5.55 Mn |
| Sep 30, 2023 | 5.06 Mn |
| Jun 30, 2023 | 5.37 Mn |
| Mar 31, 2023 | 4.80 Mn |
| Dec 31, 2022 | 4.75 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 5.42 Mn |
| Mar 31, 2022 | 5.63 Mn |
| Dec 31, 2021 | 6.02 Mn |
| Sep 30, 2021 | 5.83 Mn |
| Jun 30, 2021 | 4.99 Mn |